Terminated PHASE4 INTERVENTIONAL 1-arm NCT00927602

Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency

The Safety and Efficacy of Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism in Medical Patients With Renal Insufficiency

Sponsor: Università degli Studi dell'Insubria

Conditions Medical Patients Renal Insufficiency

Interventions fondaparinux

Updated 5 times since 2017 Last updated: Apr 23, 2012 Started: Apr 30, 2009 Primary completion: Dec 31, 2011 Completion: Mar 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

study was stopped after enrolment of about 200 patients for slow recruitment

Other terminated trials from Università degli Studi dell'Insubria

See all terminations from Università degli Studi dell'Insubria

Listed as NCT00927602, this PHASE4 trial focuses on Medical Patients and Renal Insufficiency and remains terminated or withdrawn. Sponsored by Università degli Studi dell'Insubria, it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE4

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Università degli Studi dell'Insubria

Data source: Università degli Studi dell'Insubria

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Varese, Italy